Literature DB >> 2787093

Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients.

N Høiby1, S S Pedersen.   

Abstract

During the period 1970-1987 the number of cystic fibrosis (CF) patients treated at the Danish CF Center increased from 54 to 226. The prevalence of patients with chronic P. aeruginosa infection (CF + P) increased from 35% to 59%, whereafter it decreased to 54%. The yearly incidence of new CF + P patients averaged 8.4% in 1970-1975, 17% in 1976-80, 6.5% in 1981-85, and 3% in 1986-87. These changes correlated to the increased "contact density" between CF + P and non-infected CF patients (CF-P) due to intensified treatment starting in 1976, and the reduced "contact density" due to separation of the two groups starting in 1981. The same trends were observed during an epidemic spread of a multiply resistant P. aeruginosa in the CF + P group, which was also interrupted by separation of two groups of patients, with and without the multiply resistant strain. The observed prevalences of CF + P in different age groups of patients are in accordance with a 20% incidence/year in patients older than three years. The highest probability of acquiring chronic P. aeruginosa infection was calculated to be 2%/day and the lowest 0.09%/day spent in the Centre. By employing a simple mathematical model of the spread of infectious diseases it can be shown, that the highest incidence of CF + P is present when the prevalence of CF + P is 20-80%, and that an increase in the total number of patients also increases the incidence of CF + P unless the patients are divided into smaller groups. The observations in the Danish CF Centre are in accordance with this model.

Entities:  

Mesh:

Year:  1989        PMID: 2787093     DOI: 10.1111/j.1651-2227.1989.tb11099.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  18 in total

1.  Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.

Authors:  Michael D Parkins; Bryan A Glezerson; Christopher D Sibley; Kristen A Sibley; Jessica Duong; Swathi Purighalla; Christopher H Mody; Matthew L Workentine; Douglas G Storey; Michael G Surette; Harvey R Rabin
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

2.  Comparison of ribotyping and genome fingerprinting of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  T Bennekov; H Colding; B Ojeniyi; M W Bentzon; N Høiby
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

3.  Heterogeneity of Pseudomonas aeruginosa in Brazilian cystic fibrosis patients.

Authors:  S Silbert; A L Barth; H S Sader
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

4.  Cystic fibrosis. 7. Management of cystic fibrosis in different countries. Cystic fibrosis in Copenhagen.

Authors:  C Koch; N Høiby
Journal:  Thorax       Date:  1991-05       Impact factor: 9.139

5.  Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark.

Authors:  H K Johansen; N Høiby
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

6.  Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori.

Authors:  H K Johansen; A Nørgaard; L P Andersen; P Jensen; H Nielsen; N Høiby
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

Review 7.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

8.  Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients.

Authors:  B Tümmler; U Koopmann; D Grothues; H Weissbrodt; G Steinkamp; H von der Hardt
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

Review 9.  Infection control in cystic fibrosis.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

10.  Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis.

Authors:  S Lanng; B Thorsteinsson; J Nerup; C Koch
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.